News

Filter

Current filters:

Imbruvica

1 to 9 of 26 results

Pharmacyclics acquisition strengthens AbbVie pipeline, says Kalorama

13-03-2015

US pharma company AbbVie's recent acquisition of Pharmacyclics for $21 billion strengthens AbbVie's…

AbbVieBiotechnologyHematologyImbruvicaMergers & AcquisitionsOncologyPharmacyclics

AbbVie chief executive defends Pharmacyclics deal in the face of analyst criticism

AbbVie chief executive defends Pharmacyclics deal in the face of analyst criticism

09-03-2015

As analysts question the price AbbVie paid for Pharmacyclics, AbbVie’s chief executive Richard Gonzalez…

AbbVieImbruvicaMergers & AcquisitionsPharmaceuticalPharmacyclicsUSA

FDA expands approval of Johnson & Johnson/Pharmacyclics' Imbruvica to Waldenstrom’s macroglobulinemia

FDA expands approval of Johnson & Johnson/Pharmacyclics' Imbruvica to Waldenstrom’s macroglobulinemia

30-01-2015

The US Food and Drug Administration has expanded approval of Johnson & Johnson and Pharmacyclics’ Imbruvica…

HematologyImbruvicaJohnson & JohnsonPharmaceuticalPharmacyclicsRegulationUSA

EMA backs record number of drugs for rare diseases in 2014

EMA backs record number of drugs for rare diseases in 2014

11-01-2015

The European Medicines Agency recommended the highest number of orphan designated medicines for marketing…

CyramzaEuropeGazyvaroHoloclarImbruvicaMekinistPharmaceuticalRegulationScenesseTranslarna

Janssen and Pharmacyclics submit EMA application to expand indication for Imbruvica

Janssen and Pharmacyclics submit EMA application to expand indication for Imbruvica

01-12-2014

US health care giant Johnson & Johnson’s Belgium-based subsidiary Janssen-Cilag International has submitted…

EuropeImbruvicaJanssen-CilagOncologyPharmaceuticalPharmacyclicsRegulation

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

04-11-2014

Anglo-Swedish drug major AstraZeneca and US health care giant Johnson & Johnson’s Europe-based subsidiary…

AstraZenecaBiotechnologyImbruvicaJanssenMEDI4736OncologyPharmacyclicsResearchUK

1 to 9 of 26 results

Back to top